Windlas Biotech

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0H5O01029
  • NSEID: WINDLAS
  • BSEID: 543329
INR
828.00
-55.65 (-6.3%)
BSENSE

Aug 10

BSE+NSE Vol: 1.2 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Fredun Pharma
Jagsonpal Pharma
Sakar Healthcare
Windlas Biotech
Amrutanjan Healt
Ind-Swift Labs.
Shukra Pharma.
Syncom Formul.
Hester Bios
Indoco Remedies
Fermenta Biotec.
Why is Windlas Biotech Ltd ?
1
Poor long term growth as Operating profit has grown by an annual rate 12.14% of over the last 5 years
2
Flat results in Mar 26
  • ROCE(HY) Lowest at 14.90%
  • CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 1.81 cr
3
Stock is technically in a Mildly Bearish range
  • A key technical factor - Bollinger Band has been Bearish since 19 May 2026
4
Underperformed the market in the last 1 year
  • Even though the market (BSE500) has generated returns of 0.10% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -14.58% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Windlas Biotech should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Windlas Biotech for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Windlas Biotech
-9.74%
-0.44
33.24%
Sensex
-1.65%
-0.49
12.94%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
16.15%
EBIT Growth (5y)
12.14%
EBIT to Interest (avg)
32.88
Debt to EBITDA (avg)
0.16
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
1.33
Tax Ratio
23.59%
Dividend Payout Ratio
19.93%
Pledged Shares
0
Institutional Holding
11.89%
ROCE (avg)
21.76%
ROE (avg)
11.33%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
26
Industry P/E
37
Price to Book Value
2.94
EV to EBIT
19.91
EV to EBITDA
14.07
EV to Capital Employed
4.26
EV to Sales
1.63
PEG Ratio
2.49
Dividend Yield
0.76%
ROCE (Latest)
21.40%
ROE (Latest)
11.44%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
NET SALES(Q)

Highest at Rs 238.50 cr

-3What is not working for the Company
ROCE(HY)

Lowest at 14.90%

CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 1.81 cr

Loading Valuation Snapshot...
Here's what is working for Windlas Biotech
Net Sales - Quarterly
Highest at Rs 238.50 cr and Grown
each quarter in the last five quarters
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Here's what is not working for Windlas Biotech
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 1.81 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents